17.38
price up icon2.24%   0.38
 
loading
Schlusskurs vom Vortag:
$17.00
Offen:
$17.18
24-Stunden-Volumen:
61,169
Relative Volume:
0.36
Marktkapitalisierung:
$269.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.87%
1M Leistung:
+2.54%
6M Leistung:
-17.67%
1J Leistung:
-7.41%
1-Tages-Spanne:
Value
$17.18
$17.93
1-Wochen-Bereich:
Value
$16.20
$17.95
52-Wochen-Spanne:
Value
$6.875
$37.27

Neurogene Inc Stock (NGNE) Company Profile

Name
Firmenname
Neurogene Inc
Name
Telefon
(877) 237-5020
Name
Adresse
535 W 24TH STREET, NEW YORK
Name
Mitarbeiter
107
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
NGNE's Discussions on Twitter

Compare NGNE vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NGNE
Neurogene Inc
17.38 263.33M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
491.47 117.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
803.17 82.85B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
821.96 51.58B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.40 40.75B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.07 38.33B 4.98B 69.60M 525.67M 0.5198

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-17 Eingeleitet Craig Hallum Buy
2025-05-16 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-06-11 Eingeleitet Robert W. Baird Outperform
2024-04-29 Eingeleitet Leerink Partners Outperform
2024-03-21 Eingeleitet William Blair Outperform
2024-01-08 Eingeleitet H.C. Wainwright Buy
2024-01-05 Eingeleitet Stifel Buy
2024-01-04 Eingeleitet TD Cowen Outperform
Alle ansehen

Neurogene Inc Aktie (NGNE) Neueste Nachrichten

pulisher
09:05 AM

Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit - Yahoo Finance

09:05 AM
pulisher
Feb 13, 2026

Aug Shorts: Whats the analyst consensus on Neurogene IncWeekly Investment Recap & Accurate Buy Signal Alerts - baoquankhu1.vn

Feb 13, 2026
pulisher
Feb 13, 2026

Can Neurogene Inc. outperform under higher oil pricesJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - mfd.ru

Feb 13, 2026
pulisher
Feb 12, 2026

Neurogene Inc. (NGNE) Stock Analysis: A 238% Potential Upside Awaits Investors - DirectorsTalk Interviews

Feb 12, 2026
pulisher
Feb 11, 2026

Aug Catalysts: Is Neurogene Inc a potential multi bagger2025 Trading Volume Trends & AI Based Trade Execution Alerts - baoquankhu1.vn

Feb 11, 2026
pulisher
Feb 05, 2026

Rare disease biotech Neurogene to field questions at 3 investor events - Stock Titan

Feb 05, 2026
pulisher
Feb 04, 2026

Neurogene announces inducement grant under Nasdaq Listing Rule - marketscreener.com

Feb 04, 2026
pulisher
Feb 04, 2026

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Feb 04, 2026
pulisher
Feb 04, 2026

One new Neurogene hire gets 2,820 stock options over 4 years - stocktitan.net

Feb 04, 2026
pulisher
Feb 01, 2026

Aug Fed Impact: Is Walgreens Boots Alliance Inc forming a breakout patternJuly 2025 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn

Feb 01, 2026
pulisher
Feb 01, 2026

Jobs Data: Does Neurogene Inc have a competitive edgeWeekly Gains Report & Expert-Curated Trade Recommendations - baoquankhu1.vn

Feb 01, 2026
pulisher
Jan 28, 2026

Brokers Issue Forecasts for Neurogene FY2025 Earnings - MarketBeat

Jan 28, 2026
pulisher
Jan 27, 2026

Neurogene (NASDAQ:NGNE) Now Covered by Analysts at Lifesci Capital - Defense World

Jan 27, 2026
pulisher
Jan 26, 2026

LifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform Recommendation - Nasdaq

Jan 26, 2026
pulisher
Jan 22, 2026

Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World

Jan 22, 2026
pulisher
Jan 19, 2026

Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Jan 19, 2026
pulisher
Jan 17, 2026

Aug Macro: Is Neurogene Inc stock risky to hold nowQuarterly Portfolio Report & Real-Time Stock Price Movement Reports - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 15, 2026

Risk Analysis: Can Neurogene Inc outperform under higher oil pricesTrade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 14, 2026

NGNE: NGN-401 shows durable, multi-domain gains in Rett syndrome, advancing toward commercialization - TradingView

Jan 14, 2026
pulisher
Jan 14, 2026

Neurogene (NASDAQ:NGNE) Given “Buy” Rating at HC Wainwright - Defense World

Jan 14, 2026
pulisher
Jan 14, 2026

Fund Flows: Does EXTR stock have upside surprise potentialMarket Movers & Fast Momentum Entry Tips - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 14, 2026

Market Fear: Whats the analyst consensus on Neurogene Inc2025 Market Trends & Daily Volume Surge Signals - baoquankhu1.vn

Jan 14, 2026
pulisher
Jan 13, 2026

Short Covering: Whats the analyst consensus on Neurogene IncJuly 2025 WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

HC Wainwright & Co. Reiterates Buy Rating for NGNE with $70 Pric - GuruFocus

Jan 13, 2026
pulisher
Jan 13, 2026

Neurogene doses multiple patients in Rett syndrome gene therapy trial By Investing.com - Investing.com Nigeria

Jan 13, 2026
pulisher
Jan 13, 2026

Neurogene outlines 2026 milestones for NGN-401 Rett therapy - The Globe and Mail

Jan 13, 2026
pulisher
Jan 12, 2026

Neurogene Inc. Reports Q3 2025 Financial Results - MSN

Jan 12, 2026
pulisher
Jan 12, 2026

Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin By Investing.com - Investing.com South Africa

Jan 12, 2026
pulisher
Jan 12, 2026

Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin - Investing.com Nigeria

Jan 12, 2026
pulisher
Jan 12, 2026

Market Review: Whats the analyst consensus on Neurogene IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn

Jan 12, 2026
pulisher
Jan 12, 2026

Neurogene doses multiple patients in Rett syndrome gene therapy trial - Investing.com

Jan 12, 2026
pulisher
Jan 12, 2026

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - marketscreener.com

Jan 12, 2026
pulisher
Jan 12, 2026

Neurogene Inc Announces Key Milestones for NGN-401 Gene Therapy - TradingView — Track All Markets

Jan 12, 2026
pulisher
Jan 12, 2026

Boston Herald - FinancialContent

Jan 12, 2026
pulisher
Jan 10, 2026

Neurogene Announces Positive Interim Data for NGN-401 - MSN

Jan 10, 2026
pulisher
Jan 10, 2026

User | custercountychief.comNeurogene Inc.Common Stock (Nasdaq:NGNE) Stock Quote - FinancialContent

Jan 10, 2026
pulisher
Jan 08, 2026

Is Neurogene Inc. stock a good choice for value investors2025 Volatility Report & Safe Capital Allocation Plans - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is Neurogene Inc. stock gaining market shareJuly 2025 Macro Moves & Consistent Return Investment Signals - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

What insider purchases suggest about Neurogene Inc. (UU8) stockJuly 2025 Retail & Safe Entry Point Identification - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Neurogene Inc. (NGNE) Stock Analysis: Uncovering a 208% Potential Upside in Biotechnology - DirectorsTalk Interviews

Jan 08, 2026
pulisher
Jan 08, 2026

Will Neurogene Inc. (UU8) stock attract long term capital inflows2025 Winners & Losers & Community Verified Trade Alerts - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

How Neurogene Inc. (UU8) stock correlates with oil marketsAI-Driven Market Analysis & Free Realize Exceptional Returns - Улправда

Jan 08, 2026
pulisher
Jan 07, 2026

Will Neurogene Inc. stock benefit from upcoming earnings reportsStock Price Forecasts & Minimal Investment Big Returns - ulpravda.ru

Jan 07, 2026
pulisher
Jan 06, 2026

What analysts say about Neurogene Inc UU8 stockStock Liquidity Analysis & Free Stock Predictions and Analysis - Early Times

Jan 06, 2026
pulisher
Jan 06, 2026

Shanti Educational Initiatives Limited (539921) Announces Strategic ShiftEarly Times Newspaper Jammu - Early Times

Jan 06, 2026
pulisher
Jan 05, 2026

Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - New Castle News

Jan 05, 2026
pulisher
Jan 05, 2026

Genetic medicines firm Neurogene opens its health conference talk online - Stock Titan

Jan 05, 2026
pulisher
Jan 02, 2026

Neurogene Inc.Common Stock (NQ: NGNE - FinancialContent

Jan 02, 2026
pulisher
Dec 31, 2025

Pullback Watch: Is Neurogene Inc stock a good choice for value investorsJuly 2025 Retail & AI Enhanced Trading Signals - moha.gov.vn

Dec 31, 2025
pulisher
Dec 31, 2025

Breakout Move: How Applied Industrial Technologies Inc AT4 stock reacts to monetary easingTrend Reversal & Safe Swing Trade Setup Alerts - moha.gov.vn

Dec 31, 2025
pulisher
Dec 31, 2025

Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation - Sahm

Dec 31, 2025

Finanzdaten der Neurogene Inc-Aktie (NGNE)

Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$26.45
price down icon 1.12%
$45.19
price up icon 0.87%
$101.10
price up icon 0.35%
$105.87
price up icon 0.10%
$148.75
price up icon 1.77%
biotechnology ONC
$346.07
price down icon 0.10%
Kapitalisierung:     |  Volumen (24h):